Imoxat

Country: European Union

Language: French

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

l'imidaclopride, la moxidectine

Available from:

Chanelle Pharmaceuticals Manufacturing Ltd

ATC code:

QP54AB52

INN (International Name):

imidacloprid, moxidectin

Therapeutic group:

Cats; Dogs; Ferrets

Therapeutic area:

Antiparasitic products, insecticides and repellents, macrocyclic lactones, milbemycins

Therapeutic indications:

For cats suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (Ctenocephalides felis),• the treatment of ear mite infestation (Otodectes cynotis),• the treatment of notoedric mange (Notoedres cati),• the treatment of the lungworm Eucoleus aerophilus (syn. Capillaria aerophila) (adults),• the prevention of lungworm disease (L3/L4 larvae of Aelurostrongylus abstrusus),• the treatment of the lungworm Aelurostrongylus abstrusus (adults),• the treatment of the eye worm Thelazia callipaeda (adults),• the prevention of heartworm disease (L3 and L4 larvae of Dirofilaria immitis),• the treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of Toxocara cati and Ancylostoma tubaeforme). Le médicament vétérinaire peut être utilisé dans le cadre d'une stratégie de traitement de la dermatite allergique aux puces (DCP).  For ferrets suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (Ctenocephalides felis),• the prevention of heartworm disease (L3 and L4 larvae of Dirofilaria immitis).  For dogs suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (Ctenocephalides felis),• the treatment of biting lice (Trichodectes canis),• the treatment of ear mite infestation (Otodectes cynotis), sarcoptic mange (caused by Sarcoptes scabiei var. canis), demodicosis (caused by Demodex canis),• the prevention of heartworm disease (L3 and L4 larvae of Dirofilaria immitis),• the treatment of circulating microfilariae (Dirofilaria immitis),• the treatment of cutaneous dirofilariosis (adult stages of Dirofilaria repens)• the prevention of cutaneous dirofilariosis (L3 larvae of Dirofilaria repens),• the reduction of circulating microfilariae (Dirofilaria repens),• the prevention of angiostrongylosis (L4 larvae and immature adults of Angiostrongylus vasorum),• the treatment of Angiostrongylus vasorum and Crenosoma vulpis,• the prevention of spirocercosis (Spirocerca lupi),• the treatment of Eucoleus (syn. Capillaria) boehmi (adults),• the treatment of the eye worm Thelazia callipaeda (adults),• the treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of Toxocara canis, Ancylostoma caninum and Uncinaria stenocephala, adults of Toxascaris leonina and Trichuris vulpis). Le médicament vétérinaire peut être utilisé dans le cadre d'une stratégie de traitement de la dermatite allergique aux puces (DCP).

Authorization status:

Autorisé

Authorization date:

2021-12-07

Patient Information leaflet

                                49
B. NOTICE
50
NOTICE
IMOXAT 40 MG + 4 MG SOLUTION POUR SPOT-ON POUR PETITS CHATS ET FURETS
IMOXAT 80 MG + 8 MG SOLUTION POUR SPOT-ON POUR GRANDS CHATS
1.
NOM ET ADRESSE DU TITULAIRE DE L’AUTORISATION DE MISE SUR LE
MARCHÉ ET DU TITULAIRE DE L’AUTORISATION DE FABRICATION
RESPONSABLE DE LA LIBÉRATION DES LOTS, SI DIFFÉRENT
Titulaire de l’autorisation de mise sur le marché et fabricant
responsable de la libération des lots:
Chanelle Pharmaceuticals Manufacturing Ltd.,
Loughrea, Co. Galway,
Irlande
2.
DÉNOMINATION DU MÉDICAMENT VÉTÉRINAIRE
Imoxat 40 mg + 4 mg solution pour spot-on pour petits chats et furets
Imoxat 80 mg + 8 mg solution pour spot-on pour grands chats
Imidaclopride, moxidectine
3.
LISTE DE LA (DES) SUBSTANCE(S) ACTIVE(S) ET AUTRE(S) INGRÉDIENT(S)
Chaque dose unitaire (pipette) contient:
DOSE
UNITAIRE
IMIDACLOPRIDE
MOXIDECTINE
Imoxat pour petits chats (≤ 4 kg) et furets
0,4 ml
40 mg
4 mg
Imoxat pour grands chats (> 4–8 kg)
0,8 ml
80 mg
8 mg
Excipients: alcool benzylique, butylhydroxytoluène (E321)
Solution incolore à jaune.
4.
INDICATION(S)
POUR LES CHATS atteints ou exposés au risque d’infestations
parasitaires mixtes :
•
Prévention et traitement des infestations par les puces
(_Ctenocephalides felis_),
•
Traitement de la gale des oreilles (_Otodectes cynotis_),
•
Traitement de la gale notoédrique (_Notoedres cati_),
•
Traitement de la capillariose pulmonaire à _Eucoleus aerophilus
(_syn. _Capillaria aerophila_)
(adultes),
•
Prévention de la maladie du ver du poumon (larves L3 et L4
d'_Aelurostrongylus abstrusus_),
•
Traitement de la maladie du ver du poumon à _Aelurostrongylus
abstrusus _(adultes),
•
Traitement du ver oculaire _Thelazia callipaeda _(adultes),
•
Prévention de la Dirofilariose (larves L3 et L4 de _Dirofilaria
immitis_),
•
Traitement des infestations par les nématodes gastro-intestinaux
(larves L4, adultes immatures
et formes adultes de _Toxocara cati _et _Ancylostoma tubaeforme_).
Le médicament vétérinaire peut être intégré dans
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNEXE I
RÉSUMÉ DES CARACTÉRISTIQUES DU PRODUIT
2
1.
DÉNOMINATION DU MÉDICAMENT VÉTÉRINAIRE
Imoxat 40 mg + 4 mg solution pour spot-on pour petits chats et furets
Imoxat 80 mg + 8 mg solution pour spot-on pour grands chats
2.
COMPOSITION QUALITATIVE ET QUANTITATIVE
SUBSTANCES ACTIVES:
Imoxat pour petits et grands chats et furets contient 100 mg/ml
d’imidaclopride et 10 mg/ml de
moxidectine.
Chaque dose unitaire (pipette) contient:
DOSE
UNITAIRE
IMIDACLOPRIDE
MOXIDECTINE
Imoxat pour petits chats (≤ 4 kg) et furets
0,4 ml
40 mg
4 mg
Imoxat pour grands chats (> 4–8 kg)
0,8 ml
80 mg
8 mg
EXCIPIENTS:
Alcool benzylique
1 mg/ml de butylhydroxytoluène (E321)
Pour la liste complète des excipients, voir rubrique 6.1.
3.
FORME PHARMACEUTIQUE
Solution pour spot-on
Solution incolore à jaune.
4.
INFORMATIONS CLINIQUES
4.1
ESPÈCES CIBLES
Chats, Furets.
4.2
INDICATIONS D’UTILISATION, EN SPÉCIFIANT LES ESPÈCES CIBLES
POUR LES CHATS atteints ou exposés au risque d’infestations
parasitaires mixtes :
•
Prévention et traitement des infestations par les puces
(_Ctenocephalides felis_),
•
Traitement de la gale des oreilles (_Otodectes cynotis_),
•
Traitement de la gale notoédrique (_Notoedres cati_),
•
Traitement de la capillariose pulmonaire à _Eucoleus aerophilus
(_syn. _Capillaria aerophila_)
(adultes),
•
Prévention de la maladie du ver du poumon (larves L3 et L4
d'_Aelurostrongylus abstrusus_),
•
Traitement de la maladie du ver du poumon à _Aelurostrongylus
abstrusus _(adultes),
•
Traitement du ver oculaire _Thelazia callipaeda _(adultes),
•
Prévention de la Dirofilariose (larves L3 et L4 de _Dirofilaria
immitis_),
•
Traitement des infestations par les nématodes gastro-intestinaux
(larves L4, adultes immatures
et formes adultes de _Toxocara cati _et _Ancylostoma tubaeforme_).
3
Le médicament vétérinaire peut être intégré dans un programme
thérapeutique de la Dermatite
Allergique aux Piqûres de Puces (DAPP).
POUR LES FURETS atteints ou exposés au risque d’infestations
para
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 08-06-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 08-06-2024
Public Assessment Report Public Assessment Report Bulgarian 21-09-2023
Patient Information leaflet Patient Information leaflet Spanish 08-06-2024
Public Assessment Report Public Assessment Report Spanish 21-09-2023
Patient Information leaflet Patient Information leaflet Czech 08-06-2024
Public Assessment Report Public Assessment Report Czech 21-09-2023
Patient Information leaflet Patient Information leaflet Danish 08-06-2024
Public Assessment Report Public Assessment Report Danish 21-09-2023
Patient Information leaflet Patient Information leaflet German 08-06-2024
Public Assessment Report Public Assessment Report German 21-09-2023
Patient Information leaflet Patient Information leaflet Estonian 08-06-2024
Public Assessment Report Public Assessment Report Estonian 21-09-2023
Patient Information leaflet Patient Information leaflet Greek 08-06-2024
Public Assessment Report Public Assessment Report Greek 21-09-2023
Patient Information leaflet Patient Information leaflet English 08-06-2024
Public Assessment Report Public Assessment Report English 21-09-2023
Patient Information leaflet Patient Information leaflet Italian 08-06-2024
Public Assessment Report Public Assessment Report Italian 21-09-2023
Patient Information leaflet Patient Information leaflet Latvian 08-06-2024
Public Assessment Report Public Assessment Report Latvian 21-09-2023
Patient Information leaflet Patient Information leaflet Lithuanian 08-06-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 08-06-2024
Public Assessment Report Public Assessment Report Lithuanian 21-09-2023
Patient Information leaflet Patient Information leaflet Hungarian 08-06-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 08-06-2024
Public Assessment Report Public Assessment Report Hungarian 21-09-2023
Patient Information leaflet Patient Information leaflet Maltese 08-06-2024
Public Assessment Report Public Assessment Report Maltese 21-09-2023
Patient Information leaflet Patient Information leaflet Dutch 08-06-2024
Public Assessment Report Public Assessment Report Dutch 21-09-2023
Patient Information leaflet Patient Information leaflet Polish 08-06-2024
Public Assessment Report Public Assessment Report Polish 21-09-2023
Patient Information leaflet Patient Information leaflet Portuguese 08-06-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 08-06-2024
Public Assessment Report Public Assessment Report Portuguese 21-09-2023
Patient Information leaflet Patient Information leaflet Romanian 08-06-2024
Public Assessment Report Public Assessment Report Romanian 21-09-2023
Patient Information leaflet Patient Information leaflet Slovak 08-06-2024
Public Assessment Report Public Assessment Report Slovak 21-09-2023
Patient Information leaflet Patient Information leaflet Slovenian 08-06-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 08-06-2024
Public Assessment Report Public Assessment Report Slovenian 21-09-2023
Patient Information leaflet Patient Information leaflet Finnish 08-06-2024
Public Assessment Report Public Assessment Report Finnish 21-09-2023
Patient Information leaflet Patient Information leaflet Swedish 08-06-2024
Public Assessment Report Public Assessment Report Swedish 21-09-2023
Patient Information leaflet Patient Information leaflet Norwegian 08-06-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 08-06-2024
Patient Information leaflet Patient Information leaflet Icelandic 08-06-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 08-06-2024
Patient Information leaflet Patient Information leaflet Croatian 08-06-2024
Public Assessment Report Public Assessment Report Croatian 21-09-2023

View documents history